Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs Adalimumab and Placebo in Biologic-Naive Active Psoriatic Arthritis
jRCT2080222087Phase 3
- Sponsor
- IQVIA
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in psoriatic arthritis (PsA) and plaque psoriasis (4 arms), sponsored by IQVIA.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on jRCT2080222087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222087.